Paraoxonase

PreclinicalProtein / enzyme

UUS Department of Veterans Affairs

Paraoxonase is one of 5 small molecule programs targeting Carotid Artery Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carotid Artery DiseaseActive, not recruiting

Carotid Artery DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Carotid Artery Disease

#DrugCompanyPhaseTrials

Lithobid

SSolvay Pharmaceuticals

Plavix

Bayer Aspirin

Zocor

Paraoxonase

UUS Department of Veterans Affairs

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Carotid Artery Disease1 trial

Paraoxonase and LDL Oxidation in Carotid Artery Disease

Completed·UUS Department of Veterans Affairs··NCT00011258·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Paraoxonase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paraoxonase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paraoxonase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — US Department of Veterans Affairs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: UUS Department of Veterans Affairs

Paraoxonase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Carotid Artery Disease1 trial

References

Drug Info

Quick Facts

Related News